Amgen (AMGN) Long-Term Investments (2013 - 2014)

Amgen (AMGN) recorded quarterly Long-Term Investments of $3.4 billion in Q1 2014, little changed quarter-over-quarter from $3.4 billion in Q4 2013.

Amgen (AMGN) Long-Term Investments (2013 - 2014) Analysis & Trends

Amgen's Long-Term Investments history runs 2 years deep, the most recent figure standing at $3.4 billion for Q1 2014.

In Q1 2014, Long-Term Investments changed N/A year-over-year to $3.4 billion; the TTM figure through Mar 2014 stood at $3.4 billion (changed N/A YoY), while the FY2013 annual figure was $3.4 billion, changed N/A from the prior year.
Long-Term Investments was $3.4 billion for Q1 2014 at Amgen, roughly flat from $3.4 billion in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $3.4 billion in Q1 2014 to a low of $3.4 billion in Q3 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Gsk	92,134,969.93 Bn	92,134,964.97 Bn	7.76 Bn	133.47 Mn
2	Eli Lilly	1,027.45 Bn	1,022.17 Bn	16.22 Bn	3.12 Bn
3	Johnson & Johnson	559.08 Bn	537.03 Bn	15.96 Bn	-
4	AbbVie	394.75 Bn	385.40 Bn	10.78 Bn	268.00 Mn
5	Merck	295.12 Bn	289.47 Bn	12.09 Bn	1.11 Bn
6	Amgen	186.65 Bn	174.61 Bn	5.87 Bn	-
7	Gilead Sciences	159.22 Bn	151.50 Bn	5.52 Bn	983.00 Mn
8	Pfizer	146.00 Bn	133.23 Bn	-1.21 Bn	1.63 Bn
9	Bristol Myers Squibb	113.22 Bn	102.77 Bn	8.07 Bn	366.00 Mn
10	Novartis Ag	108.02 Bn	107.33 Bn	-	100.00 Mn

Download Data